Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

The Lancet Haematology 2026

View at publisher
Authors: Anne Mea Spanjaart, Max Bakker, MSc Ralph de Vries, Barbara A. Hutten, Niels van Nieuwenhuijzen, Monique C. Minnema, Maria Theresa Kuipers, Marie José Kersten
DOI: 10.1016/s2352-3026(26)00045-1
Cited by: 1
References: 157

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment CAR-T cell therapy research Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
The Lancet Haematology
Publisher
Elsevier BV
Volume
13
Issue
5
Pages
e297–e314
Publication date
1 May 2026
Language
EN